🇧🇷Brazil

Perda de Receita por Serviços de Prescrição Farmacêutica Agora Proibidos

2 verified sources

Definition

CFF Resolution 5/2025 authorized pharmacists to prescribe medications including controlled substances and renew existing prescriptions. This generated revenue through consultation fees, higher-margin medication recommendations, and patient traffic. Federal Court suspension eliminates this revenue stream effective March 31, 2025.

Key Findings

  • Financial Impact: Estimated R$ 5,000-25,000/month per pharmacy location in lost prescription consultation revenue. Annual impact: R$ 60,000-300,000 per location for pharmacy networks.
  • Frequency: Ongoing monthly revenue loss from March 31, 2025 forward unless court decision is reversed on appeal.
  • Root Cause: Federal Court ruled CFF exceeded authority in authorizing non-physician prescription. Law 12.842/2013 reserves diagnostic and therapeutic prescription as exclusive medical acts.

Why This Matters

The Pitch: Retail pharmacies in Brasil 🇧🇷 lost estimated R$ 50K-300K annual revenue per location from pharmaceutical prescription services now legally prohibited. Forensic audit of transaction logs identifies lost transaction volume and pricing leakage.

Affected Stakeholders

Pharmacy managers (revenue impact), Clinical pharmacists (service delivery), Finance/revenue accounting

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Multa por Violação de Competência Profissional e Risco de Revogação de Alvarás

Estimated R$ 50,000-200,000 per pharmacy location in compliance remediation, system reversion, and staff retraining. Plus exposure to administrative fines (Lei 6.437/77) for operating without proper competency authorization.

Perda de Capacidade Operacional e Desperdício de Investimento em Sistemas de Prescrição

Estimated R$ 100,000-500,000 per pharmacy network in sunk IT/software costs. Plus 40-80 hours/month of staff capacity previously allocated to prescription verification now unproductive.

Erros de Decisão Estratégica Baseados em Regulação Revogada

Estimated R$ 200,000-1,000,000 per pharmacy network in erroneous hiring, system contracts, and service buildout tied to prescription authorization now suspended.

Multa por Violação de LGPD e Privacidade do Consumidor

R$ 8,497,500.00 (confirmed fine); potential industry exposure: R$ 50,000–R$ 3,000,000 per administrative proceeding depending on scale and intent.

Risco de Recusa de Cobertura de Plano de Saúde por Violação de Dados Sensíveis

Per-customer litigation cost: R$ 10,000–R$ 50,000; churn impact: 2–5% customer base loss annually; class action risk: R$ 5,000,000+.

Penalidades por Não-Conformidade ao SNGPC (Portaria 344/1998)

LOGIC-based estimate: Typical ANVISA administrative fines for non-compliance range R$ 5,000–R$ 50,000 per violation; larger networks face R$ 100,000+ for systemic SNGPC failures. Operational costs from license suspensions or revocation: loss of controlled-substance revenue (15–30% of pharmacy revenue), estimated R$ 50,000–R$ 500,000+ per pharmacy per month during suspension.

Request Deep Analysis

🇧🇷 Be first to access this market's intelligence